Cargando…

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

AIM: Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is known to be associated with type 2 diabetes mellitus (T2DM) in high rate. The improvement in hepatic function due to sodium-glucose co-transporter 2 (SGLT2) inhibitors has been reported in T2DM patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seko, Yuya, Nishikawa, Taichiro, Umemura, Atsushi, Yamaguchi, Kanji, Moriguchi, Michihisa, Yasui, Kohichiroh, Kimura, Mayumi, Iijima, Hiroaki, Hashimoto, Toshio, Sumida, Yoshio, Okanoue, Takeshi, Itoh, Yoshito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267487/ https://www.ncbi.nlm.nih.gov/pubmed/30568471 http://dx.doi.org/10.2147/DMSO.S184767

Ejemplares similares

Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor—MIG6 Axis
por: Okuda, Keiichiro, et al.
Publicado: (2021)

Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan
por: Yano, Kota, et al.
Publicado: (2020)

Potential Therapeutic Targets and Promising Agents for Combating NAFLD
por: Umemura, Atsushi, et al.
Publicado: (2022)

Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-β1/SMAD Signaling and Autophagy in Hepatic Stellate Cells
por: Kataoka, Seita, et al.
Publicado: (2021)

Aging-associated impairment in metabolic compensation by subcutaneous adipose tissue promotes diet-induced fatty liver disease in mice
por: Taketani, Hiroyoshi, et al.
Publicado: (2019)

Loss of KAP3 decreases intercellular adhesion and impairs intracellular transport of laminin in signet ring cell carcinoma of the stomach
por: Soda, Tomohiro, et al.
Publicado: (2022)

The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease
por: Seko, Yuya, et al.
Publicado: (2022)

FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease
por: Seko, Yuya, et al.
Publicado: (2019)

The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease
por: Seko, Yuya, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells
por: Takahashi, Aya, et al.
Publicado: (2021)

The Appropriate Opportunity for Evaluating Liver Fibrosis by Using the FIB-4 Index in Patients with Nonalcoholic Fatty Liver Disease in Japan
por: Seko, Yuya, et al.
Publicado: (2020)

The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals
por: Seko, Yuya, et al.
Publicado: (2020)

PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat
por: Okishio, Shinya, et al.
Publicado: (2020)

Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions
por: Fujii, Hideki, et al.
Publicado: (2017)

Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress
por: Okuda, Keiichiro, et al.
Publicado: (2021)

EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma
por: Yasui, Kohichiroh, et al.
Publicado: (2015)

Comparison of portal vein hemodynamics with ultrasound-based elastography for the prediction of liver fibrosis in patients with chronic liver disease
por: Yamaguchi, Kanji, et al.
Publicado: (2023)

Pathogenic Role of Iron Deposition in Reticuloendothelial Cells during the Development of Chronic Hepatitis C
por: Mitsuyoshi, Hironori, et al.
Publicado: (2013)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Epidemiology, Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan
por: Sumida, Yoshio, et al.
Publicado: (2020)

Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis
por: Takahashi, Aya, et al.
Publicado: (2020)

Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease
por: Kim, Young Seok, et al.
Publicado: (2013)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Procedure of Direct Hepatic Artery Puncture for the Treatment of Hepatocellular Carcinoma: Two Case Reports
por: Takashima, Hidetaka, et al.
Publicado: (2020)

A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus
por: Moriguchi, Michihisa, et al.
Publicado: (2017)

Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers
por: Kawaguchi, Takahisa, et al.
Publicado: (2018)

Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
por: Sumida, Yoshio, et al.
Publicado: (2020)

Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy
por: Nagaya, Tadanobu, et al.
Publicado: (2015)

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
por: Tokushige, Katsutoshi, et al.
Publicado: (2021)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma
por: Kanda, Tatsuo, et al.
Publicado: (2020)

Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis
por: Ando, Wataru, et al.
Publicado: (2018)

Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis
por: Stine, Jonathan G., et al.
Publicado: (2023)

Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
por: Sumida, Yoshio, et al.
Publicado: (2012)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hs1o7c51v52on7dnr4molougds